RxDoctor Payments Data

Francis Sanchez, MD

Psychiatry · West Burlington, IANPI 1639101934

Payments from drug & device makers

$307in general payments, 2019–2025

Across 15 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$124
  • Sunovion Pharmaceuticals Inc.$53
  • Neurocrine Biosciences, Inc.$41
  • Johnson & Johnson$36
  • Lundbeck LLC$25
  • Teva Pharmaceuticals USA, Inc.$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$307 in reported general payments places this provider in the 65th percentile of 245 psychiatry providers in Iowa.

See all psychiatry providers in Iowa

Medicare billing

Part B allowed, 2024
$59,355
Medicare patients
132
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole66$110,873
Invega SustennaPaliperidone Palmitate29$92,747
CaplytaLumateperone Tosylate37$66,842
FanaptIloperidone13$46,623
TrintellixVortioxetine Hydrobromide69$35,756
Risperdal ConstaRisperidone Microspheres13$28,996
SaphrisAsenapine Maleate11$13,995
Chlorpromazine Hcl67$13,528
Clozapine181$9,879
Aripiprazole255$7,925
Divalproex Sodium ErDivalproex Sodium121$7,681
Quetiapine Fumarate289$5,520
Bupropion XlBupropion Hcl255$4,075
Clonazepam468$3,353
Ziprasidone Hcl68$3,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$36$121,74242 claims
Otsuka America Pharmaceutical, Inc.Rexulti$124$110,87366 claims
AbbVieSaphris$14$13,99511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 245 psychiatry providers in Iowa.

Other psychiatry in West Burlington

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →